Takeda Pharmaceutical News

6-K: Report of foreign private issuer (related to financial reporting)

Dec 13 06:16 ET

6-K: The 148th Interim Period Business Report

Dec 2 06:06 ET

6-K: Semi-annual Securities Report

Oct 31 06:31 ET

6-K: Earnings Report for the Six-month Period Ended September 30, 2024

Oct 31 06:26 ET

6-K: Notice of the Revised Forecast of Consolidated Financials for FY2024

Oct 31 06:21 ET

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Sep 26 06:13 ET

144: Notice of proposed sale of securities pursuant to Rule 144

Aug 22 20:40 ET

SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Takeda Pharmaceutical Company Limited(4%),Takeda Ventures, Inc(4%)

Jul 31 07:51 ET

6-K: Earnings Report for the Three-month Period Ended June 30, 2024

Jul 31 06:05 ET

144: Notice of proposed sale of securities pursuant to Rule 144

Jul 10 07:19 ET

144: Notice of proposed sale of securities pursuant to Rule 144

Jul 10 07:19 ET

144: Notice of proposed sale of securities pursuant to Rule 144

Jul 10 07:19 ET

144: Notice of proposed sale of securities pursuant to Rule 144

Jul 10 07:19 ET

144: Notice of proposed sale of securities pursuant to Rule 144

Jul 10 07:19 ET

144: Notice of proposed sale of securities pursuant to Rule 144

Jul 10 07:19 ET

144: Notice of proposed sale of securities pursuant to Rule 144

Jul 10 07:19 ET

144: Notice of proposed sale of securities pursuant to Rule 144

Jul 10 07:19 ET

144: Notice of proposed sale of securities pursuant to Rule 144

Jul 10 07:19 ET

144: Notice of proposed sale of securities pursuant to Rule 144

Jul 10 07:19 ET

144: Notice of proposed sale of securities pursuant to Rule 144

Jul 10 07:14 ET